Rallybio Corporation Share Price & Technical Analysis
RLYB · $15.88 (+3.25%)
Healthcare / Biotechnology
$15.88
+3.25%
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical a…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
75% return in May, 5% avg return in past 3 year May month.
100% return in 2026, -31% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | 39% | -6% | 0% | 75% | – | – | – | – | – | – | – | 100% |
| 25 | -10% | -15% | -10% | -50% | -4% | 13% | 37% | 16% | -5% | 44% | -7% | 6% | 14% |
| 24 | -43% | 71% | -21% | 5% | -13% | -20% | 1% | -17% | 2% | -13% | 13% | -18% | -53% |
| 23 | 6% | 13% | -27% | -5% | 33% | -22% | 7% | -11% | -37% | 24% | -53% | 21% | -53% |
| 22 | 28% | -10% | -36% | 42% | 35% | -45% | 24% | 21% | 31% | -34% | -40% | 13% | 27% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Overbought
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$73.05M
P/E ratio
—
52W high
$16.00
52W low
$2.16
Volume
65,030
Beta
-1.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Rallybio Corporation share price today?
- Rallybio Corporation (RLYB) last traded around $15.88 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RLYB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RLYB. Download the app for real-time alerts.
- How can I analyze Rallybio Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.